Alpha-Ketoglutarate's Eight-Year Age Reversal Came From 42 Customers and No Control Group. The Program That Runs Controls Just Reported Nothing.
Alpha-ketoglutarate is one of the few longevity compounds that people were already swallowing before anyone called it a longevity compound. It sits in the middle of the citric acid cycle, it has been sold in gyms for two decades as a pre-workout ingredient, and it is cheap. Then came a 2020 paper in Cell Metabolism reporting that mice switched to calcium alpha-ketoglutarate chow at 18 months of age lived longer and, more strikingly, spent a much smaller share of their lives in a frail state. A year later a paper in Aging reported that 42 people taking an alpha-ketoglutarate formulation showed an average eight-year reduction in DNA methylation age after roughly seven months. Those two numbers built an entire supplement category. In 2026 the National Institute on Aging Interventions Testing Program, which tests candidate compounds in genetically heterogeneous mice at three independent laboratories simultaneously, published a report naming alpha-ketoglutarate among eight interventions that did not increase lifespan in either sex. It had already failed there once from a late start. This is what the evidence looks like when both halves are laid out next to each other.
Key Takeaways: What the Alpha-Ketoglutarate Evidence Actually Shows
Alpha-ketoglutarate is an endogenous metabolite of the citric acid cycle and a required cofactor for a family of dioxygenase enzymes that includes the TET DNA demethylases, the JmjC histone demethylases and the prolyl hydroxylases that regulate collagen synthesis and the hypoxia response. Chin and colleagues reported in Nature in 2014 that adding alpha-ketoglutarate to the growth medium extended the lifespan of adult C. elegans by roughly 50 percent, that the effect required the beta subunit of ATP synthase, and that it depended on the target of rapamycin pathway. Asadi Shahmirzadi and colleagues reported in Cell Metabolism in 2020 that mice fed calcium alpha-ketoglutarate starting at 18 months of age showed a 16.6 percent increase in female median lifespan and a 19.7 percent increase in female overall survival, with a male median lifespan increase of 9.6 percent that did not reach statistical significance. The same paper reported frailty score reductions of 46 percent in females and 41 percent in males, which is a healthspan finding rather than a lifespan finding and is the result the authors themselves emphasized. The National Institute on Aging Interventions Testing Program tested alpha-ketoglutarate in genetically heterogeneous UM-HET3 mice at three independent laboratories and found no lifespan extension, first when the compound was started at 18 months of age and again when it was started at 7 months, with the second result published in GeroScience in 2026 in a paper titled for the negative finding across eight interventions. Demidenko and colleagues reported in Aging in 2021 that 42 self-selected users of an alpha-ketoglutarate and vitamin formulation, 28 men and 14 women, showed an average reduction of 8 years in DNA methylation age measured by a saliva-based test after an average of about 7 months of use. That study had no placebo group, no randomization, no blinding and no untreated comparison group, limitations the authors stated directly, and one author was a scientific consultant and board member for the company selling the product. The claim that circulating alpha-ketoglutarate falls roughly tenfold between ages 40 and 80 traces to a 2008 review rather than to a large modern cohort with standardized metabolomics. The ABLE trial, a double-blind placebo-controlled randomized study of 1 gram of sustained-release calcium alpha-ketoglutarate against placebo for six months in 120 adults aged 40 to 60 with a biological age exceeding their chronological age, is the study designed to answer the human question, and its primary outcome, the change in a median of four blood-based methylation clocks, has not been reported. Trials of arginine alpha-ketoglutarate in resistance-trained men found no improvement in one-repetition maximum, total load volume or post-exercise brachial artery blood flow. No human study has measured lifespan, mortality or any hard clinical endpoint on alpha-ketoglutarate supplementation.
What Is Alpha-Ketoglutarate and What Does It Do in the Body?
Alpha-ketoglutarate is a molecule the body already makes constantly, sitting at the midpoint of the citric acid cycle where it acts as both a fuel intermediate and a chemical signal. Every cell running aerobic metabolism produces it as isocitrate is oxidized, and then consumes it as the cycle turns. That is only the first half of the story. Alpha-ketoglutarate is also the obligatory co-substrate for a large family of enzymes called the alpha-ketoglutarate-dependent dioxygenases, which cannot work without it. That family includes the TET enzymes that strip methyl groups from DNA, the JmjC histone demethylases that erase methyl marks from histone tails, the prolyl hydroxylases that stabilize collagen and control the hypoxia-inducible factor pathway, and enzymes involved in carnitine synthesis. This is why alpha-ketoglutarate is interesting to aging biologists rather than merely to biochemists. A metabolite that gates the enzymes writing and erasing epigenetic marks is a plausible bridge between metabolic state and the epigenome, and the epigenome is what most modern biological age tests actually measure. Alpha-ketoglutarate also participates in nitrogen handling through transamination reactions and in ammonia detoxification through glutamate. The compound sold as a supplement is usually a calcium salt, chosen because free alpha-ketoglutaric acid is unstable and unpleasant, and the calcium form is what appears in the mouse studies people cite.
Does Alpha-Ketoglutarate Really Fall Tenfold With Age?
That figure is widely repeated and rests on thinner ground than its popularity suggests. The claim is that circulating alpha-ketoglutarate declines roughly tenfold between the ages of 40 and 80, and it traces back to a 2008 review by Harrison and Pierzynowski rather than to a large modern cohort study with standardized metabolomics. It then propagated, appearing in the introduction of nearly every subsequent paper on the molecule, including the 2020 mouse study, where it serves as the motivating observation. Two things are worth separating here. The general direction of the claim is not implausible, since many metabolites shift with age and mitochondrial function changes over decades. The precision of it is another matter, and a tenfold drop is a very large number to carry on a single older source. There is a further problem specific to this metabolite. Alpha-ketoglutarate does its work inside cells, mostly inside mitochondria, and it turns over rapidly. A plasma concentration is a snapshot of the small fraction that leaked out of the compartment where the biology happens. Even if the decline is real and steep, that does not establish that oral supplementation raises the intracellular pool in the tissues that matter, which is a separate question no human study has answered directly.
The Decline That Started the Whole Idea
Circulating alpha-ketoglutarate is reported to fall roughly tenfold between the ages of 40 and 80, a figure that traces back to a 2008 review by Harrison and Pierzynowski and that appears in the introduction of almost every paper written about the molecule since. The curve here is schematic, drawn to show the shape of a tenfold decline rather than measured values, because the underlying figure does not come from a large modern cohort with standardized metabolomics. Plasma concentration is also an imperfect stand-in for a metabolite that turns over rapidly inside the cell, which is where alpha-ketoglutarate does its work.
What Did the 2020 Mouse Study Actually Find?
It found a large reduction in frailty and a lifespan gain that was concentrated in females. Asadi Shahmirzadi and colleagues, publishing in Cell Metabolism in 2020, waited until mice were 18 months old, which is roughly late middle age for a mouse, and then switched them to chow supplemented with calcium alpha-ketoglutarate. In females, median lifespan rose 16.6 percent and overall survival rose 19.7 percent. In males, median lifespan was 9.6 percent higher than control, a difference that was numerically real but did not reach statistical significance, which is a distinction that gets lost every time this study is summarized as extending lifespan. The result the authors led with was different from either number. Using a standard mouse frailty index, they reported that treated animals scored 46 percent lower in females and 41 percent lower in males, meaning the animals spent a smaller proportion of their remaining life in a visibly deteriorated state. The paper's title used the phrase compression of morbidity, and that is the honest description of what it showed. The mechanism proposed was immunological rather than metabolic. Alpha-ketoglutarate increased levels of the anti-inflammatory cytokine interleukin-10 in the treated animals, connecting the effect to the chronic low-grade inflammation that accompanies aging in mammals. Two features of this study matter for interpretation. It was conducted at a single laboratory, and the strain used was not the genetically heterogeneous stock that the field's replication program uses.
The Mouse Result That Made Alpha-Ketoglutarate Famous
Outcomes from the Cell Metabolism paper published in 2020 by Asadi Shahmirzadi and colleagues, in which mice were switched to chow containing calcium alpha-ketoglutarate at 18 months of age. Female median lifespan rose 16.6 percent and overall survival rose 19.7 percent. The male median lifespan gain of 9.6 percent was numerically larger than control but did not reach statistical significance. The finding the authors emphasized was not lifespan at all: frailty scores fell 46 percent in females and 41 percent in males, meaning the treated animals spent a smaller share of their lives in a frail state.
Why Did the Interventions Testing Program Find Nothing?
The Interventions Testing Program tested alpha-ketoglutarate under conditions designed to be harder to pass, and the compound did not pass, twice. The program is run by the National Institute on Aging and exists because the history of aging research is littered with lifespan results that appeared at one laboratory and vanished everywhere else. It runs each candidate compound in genetically heterogeneous UM-HET3 mice at three geographically separate sites at the same time, with pre-specified analysis, so that a diet effect, a local pathogen or a strain quirk cannot masquerade as biology. Alpha-ketoglutarate was tested first from a late start at 18 months of age, matching the design of the 2020 paper, and no lifespan extension appeared. It was then tested again from 7 months of age, giving the compound a much longer exposure window, and again no lifespan extension appeared. The 2026 GeroScience report carrying the second result is titled for its negative finding and lists alpha-ketoglutarate alongside astaxanthin, meclizine, mitoglitazone, pioglitazone, mifepristone, methotrexate and an atorvastatin-telmisartan combination, none of which increased lifespan in male or female mice. For context on what passing looks like, the same program has found male median lifespan gains of roughly 23 percent for rapamycin, 22 percent for acarbose, 19 percent for 17-alpha-estradiol and 14 percent for canagliflozin. The most defensible reading is not that the 2020 result was fabricated. It is that the effect depends on conditions the program's design removes, most likely genetic background, diet composition or the specific frailty measures used, and that a lifespan claim which only appears under one set of conditions is a weaker claim than the supplement market treats it as.
What Survives the Program That Runs Controls
Approximate male median lifespan gains reported by the National Institute on Aging Interventions Testing Program, which tests compounds in genetically heterogeneous UM-HET3 mice at three independent laboratories at once. Rapamycin, acarbose, 17-alpha-estradiol and canagliflozin all cleared that bar. Alpha-ketoglutarate did not, and it failed twice: once started at 18 months of age and once started at 7 months. The 2026 report carrying that result was titled for the negative finding, listing alpha-ketoglutarate alongside astaxanthin, meclizine, mitoglitazone, pioglitazone, mifepristone, methotrexate and an atorvastatin-telmisartan combination, none of which increased lifespan in either sex.
What Did the Eight-Year Biological Age Reduction Actually Measure?
It measured the change in a saliva-based DNA methylation test among 42 people who had already decided to buy and take the supplement, with nobody to compare them against. The paper by Demidenko and colleagues appeared in Aging in 2021. The 42 participants, 28 men and 14 women, had been using a formulation containing calcium alpha-ketoglutarate plus vitamins for periods ranging from about four to ten months, averaging around seven. Methylation age was measured at the start and at the end, and the average reduction came to about 8 years. There was no placebo group. There was no randomization, no blinding, and no untreated comparison group of any kind, which the authors identified as the chief limitation of the work. Two further features shape how much the number can carry. Participants were customers who selected themselves into supplementation, a group that tends to change other things about their lives at the same time, and one of the authors was a scientific consultant and board member for the company selling the product. The formulation also contained vitamins alongside the alpha-ketoglutarate, so even taking the result at face value it does not isolate the molecule. Epigenetic clocks add their own noise. Saliva-based tests have measurement variability large enough that repeat samples from the same person on the same day can differ by years, which is precisely why a control arm exists: not to prove the participants are lying, but to show what the number does in people who took nothing.
What the Eight-Year Age Reversal Study Had, and What It Did Not
Design features of the 2021 paper in Aging that reported an average eight-year reduction in DNA methylation age among 42 people taking an alpha-ketoglutarate and vitamin formulation for an average of seven months. Green marks what the study genuinely did, amber marks features that weaken the inference, and dark grey marks the controls it did not have. The authors stated the absence of a placebo group as the chief limitation themselves. Participants were customers who had already chosen to buy and take the product, and one author served as a consultant and board member for the company selling it.
Is There a Randomized Human Trial of Alpha-Ketoglutarate?
Yes, one is running, and it is the study that will actually answer the question. The ABLE trial is a double-blind, placebo-controlled randomized study of 1 gram of sustained-release calcium alpha-ketoglutarate against placebo, given for six months with a three-month follow-up, in 120 generally healthy adults aged 40 to 60 in Singapore. Enrollment was restricted to people whose biological age, measured by DNA methylation clocks, already exceeded their chronological age, which is a sensible design choice because it selects the population with the most room to move. The primary outcome is the change in the median of four blood-based methylation clocks: Hannum, Horvath, GrimAge and PhenoAge. The protocol was published in GeroScience in 2023 and a recruitment analysis appeared in 2025, but the primary outcome has not been reported. Until it is, the human evidence base for alpha-ketoglutarate as an aging intervention consists of one uncontrolled observational study of 42 people. That is worth stating plainly, because the marketing around this compound frequently implies a depth of human data that does not exist. It is also worth noting what ABLE will and will not settle. It will show whether six months of a defined dose moves methylation clocks against placebo in middle-aged adults. It will not show whether anyone lives longer, functions better at 75, or gets sick less often, because no human trial of this compound has been designed to measure any of that.
Have Men Already Been Taking Alpha-Ketoglutarate Without Knowing It?
Many have, in pre-workout formulas, and the trials from that era were not encouraging. Arginine alpha-ketoglutarate, usually abbreviated AAKG, was a staple of nitric oxide supplements through the 2000s, sold on the premise that arginine would raise nitric oxide, widen blood vessels and improve both pump and performance. Researchers tested it properly. A study of resistance-trained and untrained men found that acute AAKG supplementation produced no ergogenic benefit on one-repetition maximum or total load volume in the barbell bench press or the leg press, regardless of training status. A seven-day study in 24 physically active men measured brachial artery blood flow, plasma L-arginine, nitric oxide metabolites and asymmetric dimethylarginine after resistance exercise, and while plasma arginine rose, the changes in hemodynamics and blood flow were attributable to the exercise rather than to the supplement. Those trials tested a different salt, a different dose and a completely different endpoint from the longevity work, so they do not refute the aging hypothesis. What they do provide is a useful base rate. Alpha-ketoglutarate has been consumed by large numbers of men in gyms for two decades without producing an obvious signal of either benefit or harm, which is mildly reassuring on safety and entirely uninformative about aging.
What Is Known About Dose and Safety?
The doses in circulation come from the mouse work and from one trial protocol, not from any human dose-finding study. The ABLE trial uses 1 gram per day of sustained-release calcium alpha-ketoglutarate, which is the single most defensible number available because a research team had to justify it to an ethics committee. Commercial products commonly supply 1 to 2 grams daily, and the formulation studied in the 2021 observational paper delivered 2 grams a day across two tablets along with added vitamins. The mouse study used a dietary concentration rather than a per-kilogram dose, and translating chow percentages into human grams is guesswork that supplement marketing performs with more confidence than the arithmetic supports. On safety, alpha-ketoglutarate is an endogenous metabolite with a long history of use in sports nutrition and in clinical nutrition, and the reported adverse effects are mild and gastrointestinal: stomach discomfort, loose stools, occasional nausea. The calcium salt adds calcium, which matters for anyone already taking calcium supplements or managing a history of kidney stones. Absence of documented harm is not the same as demonstrated long-term safety, and no trial has followed supplemented humans for years. Anyone taking prescription medication, particularly for blood pressure or kidney disease, should raise it with a physician before adding a gram or two of a metabolite daily, and this article is educational rather than medical advice.
How Should a Man Read the Alpha-Ketoglutarate Evidence Right Now?
As a compound with a genuine mechanism, one memorable mouse result that did not replicate under harder conditions, and a human literature that is currently one uncontrolled study. The mechanistic case remains legitimate. Alpha-ketoglutarate really does gate the enzymes that write and erase epigenetic marks, it really did extend C. elegans lifespan by roughly 50 percent through ATP synthase and the target of rapamycin pathway, and the frailty compression seen in the 2020 mouse study is the kind of endpoint that matters more to a man in his forties than raw lifespan does. The problem is what happened next. The Interventions Testing Program exists precisely to check whether a single-laboratory lifespan finding survives contact with genetic heterogeneity and independent replication, and alpha-ketoglutarate did not survive it, at two different starting ages. That is a stronger negative than most supplement ingredients ever accumulate, because most of them are never tested there at all. On the human side, the eight-year age reversal figure is doing enormous marketing work for a study that had no comparison group, enrolled people who had already bought the product, and tested a formulation containing more than one active ingredient. A useful posture is to hold two things at once: this is a cheap, apparently well-tolerated metabolite with a real biological role, and there is currently no controlled human evidence that taking it changes anything about how a person ages. The ABLE trial will move that assessment in one direction or the other. Until it reports, the honest summary is that alpha-ketoglutarate is an interesting hypothesis being sold as a conclusion.
The Alpha-Ketoglutarate Record on One Axis
Every strand of the alpha-ketoglutarate case arranged as a single schematic map. Green marks what the evidence supports, amber marks findings that are real but weaker or narrower than the headline suggests, slate marks the results that went the wrong way, and dark grey marks claims the evidence does not carry. The pattern is a compound with a genuine mechanism and a striking single-laboratory mouse result that did not survive the one program built to replicate such things, attached to a human literature that consists of one uncontrolled observational study and a randomized trial still running.
Frequently Asked Questions
Have more questions? Contact us or explore our full peptide intelligence platform.
Related Articles
Does Telomere Length Determine Lifespan? Short Telomeres Track With Earlier Death. The Genetics Say Longer Ones Raise Cancer Risk.
Does telomere length determine lifespan? Short telomeres track with earlier death, yet genetic studies show longer ones raise the risk of several cancers.
Low-Dose Aspirin Added 8 Percent to Male Mouse Lifespan. In 19,114 Healthy Older Adults, It Added No Healthy Years and Deaths Ran Higher.
Does low-dose aspirin help longevity? It extended male mouse lifespan 8%, but the ASPREE trial in 19,114 healthy older adults found no gain and more bleeding.
Is NAD+ a Peptide? No. It Is a Coenzyme Built From Two Nucleotides, and the Peptide Label Comes From the Clinic, Not the Chemistry
Is NAD+ a peptide? No. NAD+ is a coenzyme built from two nucleotides. What NAD+ is used for, what IV NAD+ studies found, and how it differs from SS-31.